Register Now: Nobel Laureate James Rothman | SOSV Deep Tech LIVE

Reactosome

Synthetic cell platform

Company details

Reactosome is a synthetic cell platform that enables an efficient new class of nucleic acid therapies, unlocking treatments for complex diseases like solid cancers and age-related disorders by affecting 10x more genes than traditional methods

There are only a handful of scientists in the world who can make a synthetic nucleus. Only one is doing it for therapeutics

Reactosome Quote Image
Ksenia Burka, CEO
Today’s tools won't make gene therapies mainstream. Instead of delivering just DNA or RNA, why not give cells an extra nucleus?

Team

Ksenia Burka

Co-Founder & CEO

Giorgio Fracasso

Co-Founder & CTO

Get In Touch with Reactosome

Please tell us a little bit about yourself and why you'd like to get connected. Reactosome + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.